Ausgabe 5/2018
Inhalt (14 Artikel)
Open Access
Current Opinion
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Lars Erik Kristensen, Rieke Alten, Luis Puig, Sandra Philipp, Tore K. Kvien, Maria Antonia Mangues, Frank van den Hoogen, Karel Pavelka, Arnold G. Vulto
Open Access
Current Opinion
Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade®
Richard Melsheimer, Melissa Calmann, Albert DeRitis, Vinod Philip, Frank Van Gog, Lawrence Doolittle, Kavitha Goyal, Donald Neblock
Open Access
Review Article
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Beate Bittner, Wolfgang Richter, Johannes Schmidt
Open Access
Review Article
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Bushra Husain, Diego Ellerman
Review Article
Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates
Eshita Khera, Greg M. Thurber
Review Article
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
Pottayil G. Sasikumar, Murali Ramachandra
Original Research Article
Biosimilar Knowledge Among Oncology/Hematology Team Members in Colorado, USA: An Educational Initiative and Follow-Up Survey
Rovshan M. Ismailov, Zaytuna D. Khasanova
Open Access
Letter to the Editor
Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
Christopher J. Webster, Gillian R. Woollett
Letter to the Editor
Author’s Reply to Webster and Woollett: “The End of Phase 3 Clinical Trials in Biosimilars Development?”
Francois-Xavier Frapaise